LIABILITY OF THE PHARMACEUTICAL MANUFACTURER ACCORDING TO ACT NO. 7223
Burcu G. Özcan BüyüktanırABSTRACT
to the use of the pharmaceutical, there must be a causal link between the use of the pharmaceutical and the damage caused, and there must not be one of the exculpatory evidence regulated in the law. The manufacturing defect that causes the pharmaceutical to be unsafe could be like manufacturing / composition defect, fabrication defect, stimulation defect, development defect, or observation defect. The damage caused by the use of the pharmaceutical may be pecuniary or non-pecuniary. The pharmaceutical manufacturer is obliged to compensate for the damage caused by the pharmaceutical if these conditions are met. In addition, the pharmaceutical manufacturer cannot make a non-liability agreement that eliminates its liability for the damage. The period of limitations for the liability of the pharmaceutical manufacturer is regulated as three years from the date the injured party learns about the damage and the indemnity obligor and in any case ten years from the date of the damage.
Authors Orcid Profiles
Article Details
LIABILITY OF THE PHARMACEUTICAL MANUFACTURER ACCORDING TO ACT NO. 7223
77-84Burcu G. Özcan Büyüktanır
REVIEW Nobel Med 2024; 20(2): 77-84PLASMA COENZYME Q10 LEVELS OF INDIVIDUALS WITH NEWLY DIAGNOSED TYPE 2 DIABETES AND DIABETES INDIVIDUALS WITH ADVANCED MICROALBUMINURIA: A COMPARATIVE STUDY
85-92Osman Yıldırım, Birsen Demirel, Erdal Gündoğan, Hande Seven Avuk
RESEARCH ARTICLE Nobel Med 2024; 20(2): 85-92IS THE EQ-5D-5L A RELIABLE INSTRUMENT IN PATIENTS UNDERGOING CORONARY ARTERY BYPASS GRAFT SURGERY?
93-98Zeliha Özdemir Köken, Hafize Savaş, Rana Elçin Sezer Ceren, Sevilay Şenol Çelik, Göktan Aşkın
RESEARCH ARTICLE Nobel Med 2024; 20(2): 93-98ONLINE COGNITIVE BEHAVIORAL STRESS MANAGEMENT PROGRAM FOR BREAST CANCER PATIENTS
99-111Esra Savaş, Merve Keleş, Özlem Tin
RESEARCH ARTICLE Nobel Med 2024; 20(2): 99-111EVALUATION OF THE PERFORMANCE OF MACHINE LEARNING IN CLASSIFICATION OF IMAGES WITH OR WITHOUT MISSING TEETH IN PANORAMIC RADIOGRAPHS
112-118Kübra Törenek Ağırman, Kübra Başaran Aslan
RESEARCH ARTICLE Nobel Med 2024; 20(2): 112-118EFFECTS OF THE ANTIEPILEPTIC DRUGS CARBAMAZEPINE AND LEVETIRACETAM ON BONE HEALING IN RAT FRACTURE MODEL
119-127Mesut Tıkman, Evrim Duman
RESEARCH ARTICLE Nobel Med 2024; 20(2): 119-127FACTORS AFFECTING CERVICAL CANCER SCREENING BEHAVIOR IN WOMEN AGED 30-65 YEARS IN A DISTRICT IN ISTANBUL
128-134Nefise Şeker, Halim İşsever
RESEARCH ARTICLE Nobel Med 2024; 20(2): 128-134A CLASTOGENICITY STUDY WITH MITOMYCIN-C IN APLASTIC ANEMIA: DISTINGUISHING FANCONI ANEMIA
135-140Gülçin Bağatir, Şükrü Öztürk, Ayşe Gül Bayrak Tokaç, Kıvanç Çefle, Aysegül Ünüvar, Zeynep Karakaş, Ayşe Palanduz, Şükrü Palanduz
RESEARCH ARTICLE Nobel Med 2024; 20(2): 135-140DR. REFİK SAYDAM (1882-1942)
141-146Turhan ADA
A PORTRAIT Nobel Med 2024; 20(2): 141-146LIVER AND SYSTEMIC DISEASES
05-09Sebati Özdemir
REVIEW Nobel Med 2013; 9(2): 5-9AGING KIDNEY: SENESCENCE OR DISEASE?
10-14Meltem Gürsu, Rümeyza Kazancıoğlu, Savaş Öztürk
REVIEW Nobel Med 2013; 9(2): 10-14IMPORTANCE OF HOLOTRANSCOBALAMIN (HOLOTC) MEASUREMENTS IN EARLY DIAGNOSIS OF COBALAMIN DEFICIENCY, ESPECIALLY IN PATIENTS WITH BORDERLINE VITAMIN B12 CONCENTRATIONS
15-20Faruk Sönmezışık, Esma Sürmen Gür, Burak Asıltaş
RESEARCH ARTICLE Nobel Med 2013; 9(2): 15-20EVALUATION OF PHYSICAL GROWTH IN PATIENTS WITH FAMILIAL MEDITERRANEAN FEVER
21-25Celalettin Koşan, Oğuzhan Sepetçigil, Atilla Çayır, Avni Kaya, Behzat Özkan
RESEARCH ARTICLE Nobel Med 2013; 9(2): 21-25COMPARISON OF RISK INDEXES USED IN DETERMINING THE POSTOPERATIVE RESPIRATORY INSUFFICIENCY RISK
26-31Gülsüm Kavalcı, Cavidan Arar, Alkın Çolak, Nesrin Turan, Cemil Kavalcı
RESEARCH ARTICLE Nobel Med 2013; 9(2): 26-31THE EVALUATION OF PRENATAL AND ENVIROMENTAL RISK FACTORS IN CHILDREN WITH ASTHMA, ALLERGIC RHINITIS AND BRONCHIAL ASTHMA ABSTRACT
32-37Mehmet İbrahim Turan, Müferet Ergüven, Mehmet Özdemir
RESEARCH ARTICLE Nobel Med 2013; 9(2): 32-37REOPERATIONS AND MORBIDITY IN THYROID SURGERY
38-42Serkan Teksöz, Murat Özcan, Aytül Sargan, Yusuf Bukey, Recep Özgültekin, Ateş Özyeğin
RESEARCH ARTICLE Nobel Med 2013; 9(2): 38-42EFFECTS OF RAMADAN FASTING ON BLOOD PRESSURE CONTROL, LIPID PROFILE, BRAIN NATRIURETIC PEPTIDE, RENAL FUNCTIONS AND ELECTROLYTE LEVELS IN HYPERTENSIVE PATIENTS TAKING COMBINATION THERAPY
43-46İbrahim Faruk Aktürk, İsmail Bıyık, Cüneyt Koşaş, Ahmet Arif Yalçın, Mehmet Ertürk, Fatih Uzun
RESEARCH ARTICLE Nobel Med 2013; 9(2): 43-46MANAGEMENT OF A LARGE OUTBREAK CAUSED BY NOROVIRUS AND CAMPYLOBACTER JEJUNI OCCURRED IN A RURAL AREA IN TURKEY
47-51İbak Gönen
RESEARCH ARTICLE Nobel Med 2013; 9(2): 47-51FREQUENT CD99 AND FLI-1 EXPRESSIONS IN DIFFUSE LARGE B-CELL LYMPHOMA AND THEIR ASSOCIATION WITH PROLIFERATIVE AND APOPTOTIC RATES
52-56Ufuk Berber, İsmail Yılmaz, Tolga Tuncel, Zafer Küçükodacı Aptullah Haholu
RESEARCH ARTICLE Nobel Med 2013; 9(2): 52-56-
Pubmed Style
Burcu G. Özcan Büyüktanır. [İLAÇ ÜRETİCİSİNİN 7223 SAYILI ÜRÜN GÜVENLİĞİ VE TEKNİK DÜZENLEMELER KANUNUNA GÖRE HUKUKİ SORUMLULUĞU]. Nobel Med 2024; 20(2): 77-84, Turkish. -
Web Style
Burcu G. Özcan Büyüktanır. [İLAÇ ÜRETİCİSİNİN 7223 SAYILI ÜRÜN GÜVENLİĞİ VE TEKNİK DÜZENLEMELER KANUNUNA GÖRE HUKUKİ SORUMLULUĞU]. www.nobelmedicus.com/en/Article.aspx?m=1716 [Access: Mayıs 24, 2021], Turkish. -
AMA (American Medical Association) Style
Burcu G. Özcan Büyüktanır. [İLAÇ ÜRETİCİSİNİN 7223 SAYILI ÜRÜN GÜVENLİĞİ VE TEKNİK DÜZENLEMELER KANUNUNA GÖRE HUKUKİ SORUMLULUĞU]. Nobel Med 2024; 20(2): 77-84, Turkish. -
Vancouver/ICMJE Style
Burcu G. Özcan Büyüktanır. [İLAÇ ÜRETİCİSİNİN 7223 SAYILI ÜRÜN GÜVENLİĞİ VE TEKNİK DÜZENLEMELER KANUNUNA GÖRE HUKUKİ SORUMLULUĞU]. Nobel Med (2024); 20(2): 77-84, [cited Mayıs 24, 2021], Turkish. -
Harvard Style
Burcu G. Özcan Büyüktanır. (2024) [İLAÇ ÜRETİCİSİNİN 7223 SAYILI ÜRÜN GÜVENLİĞİ VE TEKNİK DÜZENLEMELER KANUNUNA GÖRE HUKUKİ SORUMLULUĞU]. Nobel Med, 20(2): 77-84, Turkish.